Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1075126 Target Snapshot

Pyruvate kinase PKLR · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
730Compounds
72Assays
0Approved Drugs
56.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Pyruvate kinase PKLR shows approved-linked disease relevance led by anemia. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P30613. Start with anemia, then reuse UniProt P30613 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with anemia, then reuse UniProt P30613 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
anemia

Pyruvate kinase PKLR shows approved-linked disease relevance led by anemia. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with anemia because it currently carries approved-linked support. Linked drugs include MITAPIVAT SULFATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Pyruvate kinase PKLR as ChEMBL target CHEMBL1075126, mapped to UniProt P30613. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Pyruvate kinase PKLR
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1075126
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P30613
Pyruvate kinase PKLR
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Pyruvate kinase PKLR is the right protein anchor across sources, using UniProt P30613 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why anemia is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NamePyruvate kinase PKLR
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP30613
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelPyruvate kinase PKLR
UniProt AccessionP30613
Component TypeProtein
Sequence Length574 aa

Pyruvate kinase PKLR

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Pyruvate kinase PKLR, mapped to UniProt P30613. Sequence length is 574 aa.

Mapped IDP30613
Review namePyruvate kinase PKLR
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Pyruvate kinase PKLR shows approved-linked disease relevance led by anemia. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
anemia
1 linked drug · 1 direct · 1 efficacy
Linked drugMITAPIVAT SULFATE
Approved-linked Approved
familial hemolytic anemia
1 linked drug · 1 direct · 1 efficacy
Linked drugMITAPIVAT SULFATE
Approved-linked Approved
genetic disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugMITAPIVAT SULFATE
Late clinical Phase III
Alpha-thalassemia
1 linked drug · 1 direct · 1 efficacy
Linked drugMITAPIVAT
Late clinical Phase III
Beta-thalassemia
1 linked drug · 1 direct · 1 efficacy
Linked drugMITAPIVAT
Clinical signal Phase II
sickle cell anemia
2 linked drugs · 2 direct · 2 efficacy
Linked drugETAVOPIVAT
Linked drugMITAPIVAT
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with anemia because it currently carries approved-linked support. Linked drugs include MITAPIVAT SULFATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseanemia
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Phase III
1
Phase II
Assay Mix

Activity Type Distribution

IC5053.0
KI1.0
EC502.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL6338 7.55 IC50 28.0 Preclinical
CHEMBL6246 7.5 IC50 32.0 Clinical
CHEMBL5556210 7.16 IC50 70.0 Preclinical
CHEMBL5429790 6.92 IC50 120.0 Preclinical
CHEMBL5204170 6.82 IC50 150.0 Preclinical
CHEMBL5209097 6.8 IC50 160.0 Preclinical
CHEMBL175336 6.7 IC50 200.0 Preclinical
CHEMBL5176753 6.7 IC50 200.0 Preclinical
CHEMBL5208105 6.7 IC50 200.0 Preclinical
CHEMBL5532261 6.54 EC50 290.0 Preclinical
Distribution

pChEMBL Value Distribution

9
5.0
12
5.5
4
6.0
9
6.5
1
7.0
2
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

76
Total Assays
37
Tested Compounds
3
Assay Types
Binding — 63 assays, 37 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 45 28 5.8
assay format 9 7 6.4
cell-based format 7 2 6.4
subcellular format 2 0 —
Functional — 12 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 12 0 —
ADME — 1 assays, 3 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 3 5.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine